1,25-Dihydroxyvitamin D3 and transforming growth factor-β act synergistically to override extinction of liver/bone/kidney alkaline phosphatase in osteosarcoma hybrid cells

Teresa L Johnson-pais, Robin J Leach

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

In this study, a somatic cell genetic approach was used to study the regulation of liver/bone/kidney alkaline phosphatase (ALPL) gene expression in osteoblasts. ALPL plays an important role in skeletal mineralization and serves as a good index of bone formation. A series of intertypic hybrids constructed by fusion of the human osteosarcoma TE-85 with the mouse fibrosarcoma La t- demonstrated a 10-fold reduction of ALPL steady-state mRNA and enzyme activity, a phenomenon termed extinction. Hybrid subclones which reexpressed ALPL contained reduced numbers of fibroblast chromosomes compared to earlier passages. This suggests that a trans-acting negative regulatory factor expressed from the fibroblast genome regulates ALPL expression. Two factors known to influence ALPL expression are 1,25- dihydroxyvitamin D3 (1,25D3) and transforming growth factor-β1 (TGFβ1). 1,25D3 is involved in mobilizing bone calcium stores and TGFβ1 plays a critical role in bone remodeling. The extinguished hybrids were exposed to 1,25D3, TGFβ1, and a combination of these factors. For two hybrids, the combination induced reexpression of ALPL activity to levels comparable to the TE-85 parent, indicating a competition between the factors and the extinguisher(s). Neither factor alone could induce ALPL reexpression to the levels observed with the combination. In only one hybrid, the combination of factors synergistically increased ALPL expression. These data help define the cis sequence element(s) in the ALPL promoter which are involved in the negative regulation of this gene.

Original languageEnglish (US)
Pages (from-to)67-74
Number of pages8
JournalExperimental Cell Research
Volume226
Issue number1
DOIs
StatePublished - Jul 10 1996

Fingerprint

Hybrid Cells
Calcitriol
Transforming Growth Factors
Osteosarcoma
Alkaline Phosphatase
Kidney
Bone and Bones
Liver
Fibroblasts
Bone Remodeling
Fibrosarcoma
Osteoblasts
Osteogenesis
Chromosomes
Genome
Calcium
Gene Expression
Messenger RNA
Enzymes
Genes

ASJC Scopus subject areas

  • Cell Biology

Cite this

@article{3263315aabfb465eabff4c8fd524fb1e,
title = "1,25-Dihydroxyvitamin D3 and transforming growth factor-β act synergistically to override extinction of liver/bone/kidney alkaline phosphatase in osteosarcoma hybrid cells",
abstract = "In this study, a somatic cell genetic approach was used to study the regulation of liver/bone/kidney alkaline phosphatase (ALPL) gene expression in osteoblasts. ALPL plays an important role in skeletal mineralization and serves as a good index of bone formation. A series of intertypic hybrids constructed by fusion of the human osteosarcoma TE-85 with the mouse fibrosarcoma La t- demonstrated a 10-fold reduction of ALPL steady-state mRNA and enzyme activity, a phenomenon termed extinction. Hybrid subclones which reexpressed ALPL contained reduced numbers of fibroblast chromosomes compared to earlier passages. This suggests that a trans-acting negative regulatory factor expressed from the fibroblast genome regulates ALPL expression. Two factors known to influence ALPL expression are 1,25- dihydroxyvitamin D3 (1,25D3) and transforming growth factor-β1 (TGFβ1). 1,25D3 is involved in mobilizing bone calcium stores and TGFβ1 plays a critical role in bone remodeling. The extinguished hybrids were exposed to 1,25D3, TGFβ1, and a combination of these factors. For two hybrids, the combination induced reexpression of ALPL activity to levels comparable to the TE-85 parent, indicating a competition between the factors and the extinguisher(s). Neither factor alone could induce ALPL reexpression to the levels observed with the combination. In only one hybrid, the combination of factors synergistically increased ALPL expression. These data help define the cis sequence element(s) in the ALPL promoter which are involved in the negative regulation of this gene.",
author = "Johnson-pais, {Teresa L} and Leach, {Robin J}",
year = "1996",
month = "7",
day = "10",
doi = "10.1006/excr.1996.0203",
language = "English (US)",
volume = "226",
pages = "67--74",
journal = "Experimental Cell Research",
issn = "0014-4827",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - 1,25-Dihydroxyvitamin D3 and transforming growth factor-β act synergistically to override extinction of liver/bone/kidney alkaline phosphatase in osteosarcoma hybrid cells

AU - Johnson-pais, Teresa L

AU - Leach, Robin J

PY - 1996/7/10

Y1 - 1996/7/10

N2 - In this study, a somatic cell genetic approach was used to study the regulation of liver/bone/kidney alkaline phosphatase (ALPL) gene expression in osteoblasts. ALPL plays an important role in skeletal mineralization and serves as a good index of bone formation. A series of intertypic hybrids constructed by fusion of the human osteosarcoma TE-85 with the mouse fibrosarcoma La t- demonstrated a 10-fold reduction of ALPL steady-state mRNA and enzyme activity, a phenomenon termed extinction. Hybrid subclones which reexpressed ALPL contained reduced numbers of fibroblast chromosomes compared to earlier passages. This suggests that a trans-acting negative regulatory factor expressed from the fibroblast genome regulates ALPL expression. Two factors known to influence ALPL expression are 1,25- dihydroxyvitamin D3 (1,25D3) and transforming growth factor-β1 (TGFβ1). 1,25D3 is involved in mobilizing bone calcium stores and TGFβ1 plays a critical role in bone remodeling. The extinguished hybrids were exposed to 1,25D3, TGFβ1, and a combination of these factors. For two hybrids, the combination induced reexpression of ALPL activity to levels comparable to the TE-85 parent, indicating a competition between the factors and the extinguisher(s). Neither factor alone could induce ALPL reexpression to the levels observed with the combination. In only one hybrid, the combination of factors synergistically increased ALPL expression. These data help define the cis sequence element(s) in the ALPL promoter which are involved in the negative regulation of this gene.

AB - In this study, a somatic cell genetic approach was used to study the regulation of liver/bone/kidney alkaline phosphatase (ALPL) gene expression in osteoblasts. ALPL plays an important role in skeletal mineralization and serves as a good index of bone formation. A series of intertypic hybrids constructed by fusion of the human osteosarcoma TE-85 with the mouse fibrosarcoma La t- demonstrated a 10-fold reduction of ALPL steady-state mRNA and enzyme activity, a phenomenon termed extinction. Hybrid subclones which reexpressed ALPL contained reduced numbers of fibroblast chromosomes compared to earlier passages. This suggests that a trans-acting negative regulatory factor expressed from the fibroblast genome regulates ALPL expression. Two factors known to influence ALPL expression are 1,25- dihydroxyvitamin D3 (1,25D3) and transforming growth factor-β1 (TGFβ1). 1,25D3 is involved in mobilizing bone calcium stores and TGFβ1 plays a critical role in bone remodeling. The extinguished hybrids were exposed to 1,25D3, TGFβ1, and a combination of these factors. For two hybrids, the combination induced reexpression of ALPL activity to levels comparable to the TE-85 parent, indicating a competition between the factors and the extinguisher(s). Neither factor alone could induce ALPL reexpression to the levels observed with the combination. In only one hybrid, the combination of factors synergistically increased ALPL expression. These data help define the cis sequence element(s) in the ALPL promoter which are involved in the negative regulation of this gene.

UR - http://www.scopus.com/inward/record.url?scp=0030578417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030578417&partnerID=8YFLogxK

U2 - 10.1006/excr.1996.0203

DO - 10.1006/excr.1996.0203

M3 - Article

VL - 226

SP - 67

EP - 74

JO - Experimental Cell Research

JF - Experimental Cell Research

SN - 0014-4827

IS - 1

ER -